ISSN 1866-8836
Клеточная терапия и трансплантация

Change template to: announce
Volume 11, Number 1
04/15/2022 03:53:21 pm
Volume 11, Number 1
Editor-in-Chief
Kulagin A. D. (St. Petersburg, Russia)
Co-Editors-in-Chief
Wagemaker G. (Rotterdam, Netherlands)
Zander A. R. (Hamburg, Germany)
Deputy Editor
Fehse B. (Hamburg, Germany)
Managing Editor
Chukhlovin A. B. (St. Petersburg, Russia)
Editorial Board
Aleynikova O. V. (Minsk, Belarus)
Borset M. (Trondheim, Norway)
Chechetkin A. V. (St. Petersburg, Russia)
Fibbe W. (Leiden, Netherlands)
Gale R. P. (Los Angeles, USA)
Galibin O. V. (St. Petersburg, Russia)
Hehlmann R. (Mannheim, Germany)
Hölzer D. (Frankfurt a.M., Germany)
Klimko N. N. (St. Petersburg, Russia)
Kolb H.-J. (München, Germany)
Kröger N. (Hamburg, Germany)
Lange C. (Hamburg, Germany)
Mamaev N. N. (St. Petersburg, Russia)
Mikhailova N. B. (St. Petersburg, Russia)
Moiseev I. S. (St. Petersburg, Russia)
Nagler A. (Tel-Aviv, Israel)
Nemkov A. S. (St. Petersburg, Russia)
Paramonov I. V. (Kirov, Russia)
Roumiantsev A. G. (Moscow, Russia)
Savchenko V. G. (Moscow, Russia)
Smirnov A. V. (St. Petersburg, Russia)
Uss A. L. (Minsk, Belarus)
Zubarovskaya L. S. (St. Petersburg, Russia)
In this Issue

Editorial

Pavlov University: 125 years in blood research

Professor Alexander D. Kulagin, Editor-in-Chief, Cellular Therapy and Transplantation Journal

Review articles

High-dose chemotherapy with autologous hemopoietic stem cell transplantation in children with retinoblastoma. Literature review and case series

Karina A. Sergeenko1,3, Yana Yu. Dokuchaeva1, Irina O. Kostareva1, Tim Z. Aliev1, Anna Yu. Elfimova1, Nikolay G. Stepanian1, Yury V. Lozovan1, Natalya A. Burlaka1, Natalya V. Sidorova2, Elena B. Machneva1,2, Tatyana V. Gorbunova1,5, Tatyana L. Ushakova1,3, Vladimir G. Polyakov1,3,4,5, Kirill I. Kirgizov1,5, Svetlana R. Varfolomeeva1,2,5

Clinical studies

Peripheral blood stem cell transplantation from haploidentical and unrelated versus related donors for acute leukemia in children, adolescents and young adults (CAYA): A competing risk analysis

Tahereh Rostami1, Mohammad R. Rostami2, Azadeh Kiumarsi1, Amir Kasaeian3, Neda Alijani4, Hosein K. Fumani2, Soroush Rad2, Davood Babakhani2, Tanaz Bahri2, Mohammad Vaezi2, Maryam Barkhordar2, Seied A. Mirhosseini2, Seied A. Mousavi2

Pre- and post-transplantation factors associated with primary graft failure and severe poor graft function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia

Elena V. Morozova, Tatiana A. Rudakova, Julia Ju. Vlasova, Maria V. Barabanshchikova, Tatiana L. Gindina, Alexander L. Alyanskiy, Maria D. Vladovskaya, Ivan S. Moiseev, Ludmila S. Zubarovskaya, Alexander D. Kulagin

Microbiota of nasal cavity in sinusitis following hematopoietic stem cell transplantation

Oleg I. Dolgov1, Sergey A. Karpishchenko1, Ekaterina S. Utimisheva1, Diana A. Grigoryanz1, Anna A. Spiridonova1,2, Ivan S. Moiseev1, Ludmila S. Zubarovskaya1, Alexei B. Chukhlovin1, Alexander D. Kulagin1

Clinical case

A case report of haploidentical hematopoietic stem cell transplantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy after kidney transplantation

Elena N. Parovichnikova, Vera A. Vasilyeva, Olga A. Aleshina, Mariya V. Dovydenko, Larisa A. Kuzmina, Mikhail Yu. Drokov, Irina A. Lukyanova, Vera V. Troitskaya, Evgenii E. Zvonkov, Alla M. Kovrigina, Valery G. Savchenko

Experimental studies

Therapeutic potential of mouse bone marrow mesenchymal stromal cells transplantation in ameliorating of CCL4-induced liver damage (in vivo study)

Dima Joujeh1, Abduljalil Ghrewaty1, Chadi Soukkarieh2, Adnan Almarrawi1, Jamal Abdul Naser Darwicha3

Editorial

Pavlov University: 125 years in blood research

Download PDF version

Professor Alexander D. Kulagin, Editor-in-Chief, Cellular Therapy and Transplantation Journal

In 2022, the First St. Petersburg State Medical University (Pavlov University) is celebrating its 125th anniversary. The studies in clinical hematology and immunology developed here since early XX century at the Chair of Faculty Therapy. Its future head, Prof. Georg F. Lang later became a famous cardiologist. However, his Doctor’s Thesis (1901) was dedicated to osmotic resistance of red blood cells in stomach cancer and other malignancies. He presented original experimental studies on regulation of red blood cells and hemolysis. Later on, professor T. S. Istamanova headed the chair, being the best successor of his school. She was among founders of functional hematology, proceeded with studies in physiology and pathology of erythropoiesis performed since 20s. Her experimental works concerned the role of spleen in red blood cell destruction, neurogenic regulation of hematopoiesis, functional significance of reticulocytosis in hematopoietic function. Prof. T. S. Istamanova was deeply involved into clinical aspects of polycythemia. Functional dynamics of erythroid cells was extensively studied over 40s and 50s, especially, using innovative assays of hemoglobin metabolism with 59Fe and other radionuclides.

Review articles

High-dose chemotherapy with autologous hemopoietic stem cell transplantation in children with retinoblastoma. Literature review and case series

Download PDF version

Karina A. Sergeenko1,3, Yana Yu. Dokuchaeva1, Irina O. Kostareva1, Tim Z. Aliev1, Anna Yu. Elfimova1, Nikolay G. Stepanian1, Yury V. Lozovan1, Natalya A. Burlaka1, Natalya V. Sidorova2, Elena B. Machneva1,2, Tatyana V. Gorbunova1,5, Tatyana L. Ushakova1,3, Vladimir G. Polyakov1,3,4,5, Kirill I. Kirgizov1,5, Svetlana R. Varfolomeeva1,2,5

1 N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
2 Russian State Clinical Hospital, N. I. Pirogov Russian National Research Medical University, Moscow Russia
3 Russian Medical Academy for Continuous Professional Education, Moscow, Russia
4 N. I. Pirogov Russian National Medical University, Moscow, Russia
5 Department of Continious Medical Education, N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia


Correspondence:
Dr. Karina A. Sergeenko, Resident, Department of Pediatric Oncology, Russian Medical Academy for Continuous Professional Education, Moscow, Russia
E-mail: karina_s19@mail.ru


Citation: Sergeenko KA, Dokuchaeva YaYu, Kostareva IO et al. High-dose chemotherapy with autologous hemopoietic stem cell transplantation in children with retinoblastoma. Literature review and case series. Cell Ther Transplant 2022; 11(1): 6-12.

Retinoblastoma (RB) is the most common malignant eye tumor in children accounting for 10-15% of all cancer cases in infants. In spite of generally good standard treatment results there is still a subgroup of high-risk patients with by unfavorable prognosis, which warrants the search for additional treatment strategies. These children may benefit from treatment intensification in form of high-dose consolidation with subsequent autologous hemopoietic stem cell therapy (auto-HSCT). We here describe a case series illustrating N. N. Blokhin Cancer Center experience in this area.

Materials and methods

In 2021 a total of 3 children with high-risk RB were treated in N. N. Blokhin Cancer Center receiving high-dose regimen consisting of carboplatin (total dose of 1250 mg/m2), etoposide (1750 mg/m2), and cyclophosphamide (6000 mg/m2) with subsequent auto-HSCT.

Results

All 3 patients engrafted in day +11, +14, and +17 after auto-HSCT. The early post-transplant period was complicated by oral mucositis, neutropenic enterocolitis, and febrile neutropenia. One patient had a single episode of seizures due to hyponatremia. With a median follow-up of 6 (4-10) months two patients are alive and disease-free, one died due to disease progression.

Conclusions

The high-dose consolidation with subsequent auto- HSCT is a feasible option for high-risk RB patients. It is characterized by acceptable toxicity and is a potentially effective for disease control. In order to further evaluate the long-term results, there is a need for a larger prospective patient cohort. The multicenter study design may be beneficial in these settings.

Keywords

Autologous hematopoietic stem cell transplantation, retinoblastoma, children, high-dose chemotherapy.

Clinical studies

Peripheral blood stem cell transplantation from haploidentical and unrelated versus related donors for acute leukemia in children, adolescents and young adults (CAYA): A competing risk analysis

Download PDF version

Tahereh Rostami1, Mohammad R. Rostami2, Azadeh Kiumarsi1, Amir Kasaeian3, Neda Alijani4, Hosein K. Fumani2, Soroush Rad2, Davood Babakhani2, Tanaz Bahri2, Mohammad Vaezi2, Maryam Barkhordar2, Seied A. Mirhosseini2, Seied A. Mousavi2

1 Department of Pediatric Cell Therapy, Research Institute for Oncology, Hematology and Cell Therapy (RIOHCT), Shariati Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran
2 Research Institute for Oncology, Hematology and Cell Therapy (RIOHCT), Shariati Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran
3 Department of Biostatistics and Epidemiology, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran
4 Department of lnfectious Diseases, Shariati Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran


Correspondence:
Dr. Azadeh Kiumarsi, MD, Assistant Professor, Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatric Cell Therapy, Research Institute for Oncology, Hematology and Cell Therapy, Shariati Hospital, Kargar Shomali Street, 1411713131, Tehran, Iran
Phone: +98 9121037104
Fax: +98 (21) 8802 9397
Email: akiumarsi@sina.tums.ac.ir


Citation: Tahereh Rostami, Mohammad R. Rostami, Azadeh Kiumarsi et al. Peripheral blood stem cell transplantation from haploidentical and unrelated versus related donors for acute leukemia in children, adolescents and young adults (CAYA): A competing risk analysis. Cell Ther Transplant 2022; 11(1): 24-35.

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative treatment for acute leukemia. Various parameters have significant impact on the final results of HSCT, such as donor type, stem cell source, and the applied conditioning regimen. In the absence of HLA-matched related or unrelated donors, haploidentical donors present a possible alternative for the patients with indications for HSCT. The present single-center study compared the outcomes of HSCT from different donor types using a radiation-free MAC regimen. We compared the results of unmanipulated peripheral blood stem cell transplantation (PBSCT) from matched, or mismatched related, and unrelated donors with those from haploidentical donors in the children, adolescents and young adults (CAYA) treated for acute leukemia.

Patients and methods

In this retrospective study performed since 2014 to 2021, we have evaluated the clinical outcomes among CAYA patients with acute leukemia who underwent peripheral blood T cell-replete HSCT from haploidentical donors versus unrelated donors (including 10/10 or 9/10 HLA-matched), and versus related donors (including 10/10 or 9/10 HLA-matched). The myeloablative conditioning for HSCT was performed as irradiation-free regimen including busulfan and cyclophosphamide. GvHD prophylaxis was based on administration of cyclosporine A in all the patients, accomplished by rabbit anti-human thymocyte globulin in HSCT from unrelated and haploidentical donors, and post-transplant cyclophosphamide in cases of haploidentical donors. For statistical evaluation, an adjusted multivariable proportional hazard Cox and competing risk analyses were used.

Results

Median follow-up time period was 28.7 months (95% CI: 21.9-34.9). Three-year overall survival rate (OS) and GvHD-free/relapse-free survival (GFRFS) rate were 68.81% (95% CI: 60.08%-76.01%) and 44.19% (95% CI: 35.52%-52.49%), respectively. The patients who underwent HSCT from unrelated HLA-matched donors had the lowest OS and GFRFS compared to other donor types. The 3-year non-relapse mortality (NRM) in all patients was 7.84% (95% CI 4.36-12.62). Adjusted multivariable modeling of OS showed that the hazard of death in patients who had undergone HSCT from an unrelated donor, was 3.6 times more than for the patients who underwent HSCT from their haploidentical donors (P=0.05). Likewise, the hazard of NRM after HSCT from unrelated donors was 6 times more than with haploidentical donors (P=0.002). However, the relapse incidence was not significantly different between the two mentioned groups.

Conclusions

In this study, HSCT from haploidentical donors was associated with superior survival rates compared to HSCT from unrelated HLA-matched donors. Hence, haploidentical transplantation with peripheral blood stem cells could be a practical and valuable clinical option that offers a reasonable opportunity for the disease control in CAYA patients with acute leukemia requiring HSCT and lacking matched available donors.

Keywords

Acute leukemia, allogeneic hematopoietic stem cell transplantation, matched related donors, unrelated donors, haploidentical donors, clinical outcomes.

Clinical studies

Pre- and post-transplantation factors associated with primary graft failure and severe poor graft function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia

Download PDF version

Elena V. Morozova, Tatiana A. Rudakova, Julia Ju. Vlasova, Maria V. Barabanshchikova, Tatiana L. Gindina, Alexander L. Alyanskiy, Maria D. Vladovskaya, Ivan S. Moiseev, Ludmila S. Zubarovskaya, Alexander D. Kulagin

RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantology, Pavlov University, St. Petersburg, Russia


Correspondence:
Dr. Elena V. Morozova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transpantology, Pavlov University, 6-8 L.Tolstoy St, 197022, St. Petersburg, Russia
Phone: +7 (911) 927-82-29
E-mail: dr_morozova@mail.ru


Citation: Morozova EV, Rudakova TA, Vlasova JJ, et al. Pre- and post-transplantation factors associated with primary graft failure and severe poor graft function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Cell Ther Transplant 2022; 11(1): 13-23.

Allogeneic stem cell transplantation (allo-HSCT) is used worldwide for long-term management and cure of hematological malignancies, still remaining a valuable option for treatment of chronic myeloid leukemia (CML) in all fit patients who are unable to achieve a durable complete cytogenetic response after treatment with tyrosine kinase inhibitors (TKIs), and in advanced-phase disease. Along with relapse risk, the unfavorable HSCT results may be associated with primary graft failure (PrGF), or poor graft function (PoGF). Hence, the aim of our study was to assess frequency and outcome of PrGF and severe poor graft function (sPGF) after allo-HSCT in CML patients.

Patients and methods

We performed a retrospective analysis of 121 consecutive patients with CML who received allo-HSCT in the RM Gorbacheva Research Institute at the Pavlov University over 25 years. HSCT was indicated in cases of advanced-phase disease, or TKI resistance/intolerance of CML patients. BCR/ABL transcript levels and additional chromosomal abnormalities were used as laboratory markers of advanced disease. 80 patients (66%) were transplanted in chronic phase (CP); 41 patients (34%) were in acceleration phase (AP), or blast crisis (BC) at the time of HSCT. Matched unrelated donors were used in 65% of the cases; matched related donors, in 28%, and haploidentical donors, in 7% of cases.

Results

Engraftment was documented in 106 (88%) patients. Post-transplant relapses were registered in 31 patients within 15-333 days after HSCT. PrGF was documented in 8 cases (7%). Two patients developed secondary graft failure within two months after initial engraftment, with lethal infectious complications. Severe poor graft function (PoGF) was diagnosed in 11 cases (9%) at cumulative incidence of 10% within 1 year post-transplant. Among various pre-transplant characteristics, age factor, and, especially, presence of additional chromosomal abnormalities (ACA) were associated with cumulative incidence of PrGF and sPGF after HSCT. I.e., PrGF was 14% in the group with detectable ACA versus 3% in the group without ACA, (p=0.02), whereas incidence of sPGF in patients with ACA was 2% versus 12% in those without ACA (p=0.09). The incidence of post-transplant relapses did not differ in the patients with PrGF and sPGF.

Conclusions

Primary graft failure (PrGF) contributes to the non-relapse mortality during the first year after allo-HSCT in CML patients. Emergence of post-transplant relapses was not associated with PrGF and sPGF in CML. Further assessment of risk factors for the graft failure or poor graft function is required in order to improve the results of HSCT technologies.

Keywords

Chronic myeloid leukemia, hematopoietic stem cell transplantation, indications, graft failure, risk factors.

Clinical studies

Outcomes of liver transplantation to the patients with hepatocellular carcinoma from living donors versus transplants from deceased donors

Download PDF version

Mohamed R. Abdelfattah, Hussein Elsiesy

Department of Surgery, Faculty of Medicine, University of Alexandria, Alexandria, Egypt


Correspondence:
Prof. Dr. Mohamed Rabei Abdelfattah, Associate Professor, Department of Surgery, Faculty of Medicine, University of Alexandria, Azzaritta, Alexandria, Egypt, PO BOX 21131
Phone: 002010 2306 1111
Email: mohamad.rabie@gmail.com


Citation: Abdelfattah MR, Elsiesy H. Outcomes of liver transplantation to the patients with hepatocellular carcinoma from living donors versus transplants from deceased donors. Cell Ther Transplant 2022; 11(1): 43-49.

Our objective was to compare overall and tumor-free survival for the hepatocellular carcinoma (HCC) patients subjected to liver transplantation from living donor (LDLT) versus liver transplantation from deceased donor (DDLT) treated at our center.

Patients and methods

Seventy-three patients underwent liver transplantation for HCC staged according to Milan criteria (MC). The cases have been divided into two groups: (a) forty-four patients transplanted by means of LDLT, and (b) twenty-nine patients underwent DDLT. The patients beyond MC, or those who underwent downstaging locoregional therapy were excluded from the study.

Results

Overall survival outcomes at 5 years were, respectively, 80.3% vs 70.4%, in LDLT and DDLT groups whereas tumor-free survival was 79.1% vs 76% for LDLT and DDLT cases. LT from living donors showed slightly better patients’ survival compared to liver transplantation from deceased donors DDLT (P=0.09). However, the difference in tumor-free survival between both groups was virtually absent (P=0.6).

Conclusion

The present study confirmed that LDLT, while offering a slightly better overall survival, is associated with similar terms of tumor-free survival compared to transplants from deceased donors. This similarity is especially clear when avoiding biases caused by different tumor features and analyzing a perfectly matched cohort of patients presenting with HCC classified according to the Milan criteria.

Keywords

Hepatocellular carcinoma, liver transplant, living donor, deceased donor, survival.

Clinical studies

Microbiota of nasal cavity in sinusitis following hematopoietic stem cell transplantation

Download PDF version

Oleg I. Dolgov1, Sergey A. Karpishchenko1, Ekaterina S. Utimisheva1, Diana A. Grigoryanz1, Anna A. Spiridonova1,2, Ivan S. Moiseev1, Ludmila S. Zubarovskaya1, Alexei B. Chukhlovin1, Alexander D. Kulagin1

1 Pavlov University, St. Petersburg, Russia
2 St. Petersburg Pasteur Institute, St. Petersburg, Russia


Correspondence:
Dr. Oleg I. Dolgov, Department of Otorhinolaryngology, Pavlov University, 6-8 Tolstoy St, 197022, St. Petersburg, Russia
Phone: +7 (921) 845-03-51
E-mail: oidolgov@yandex.ru


Citation: Dolgov OI, Karpishchenko SA, Utimisheva ES, et al. Microbiota of nasal cavity in sinusitis following hematopoietic stem cell transplantation. Cell Ther Transplant 2022; 11(1): 36-42.

Hematopoietic stem cell transplantation (HSCT) is often accompanied by infectious complications. The aim of this study was a comparative evaluation of facultative anaerobic microbiota members of nasal and paranasal cavity in sinusitis, which often develops in immunocompromised patients, due to intensive chemotherapy and massive antibiotic treatment followed by hematopoietic cell transplantation (HSCT).

Materials and methods

The study involved 194 patients with various myelo- and lymphoproliferative diseases aged 1 to 62 years who underwent intensive chemotherapy and allogeneic HSCT. As based on appropriate clinical indications, the biomaterial was taken from patients (washings from the paranasal sinuses and/or nasal swabs) within the time period of +100 to +180 days after allogeneic HSCT. We studied 124 samples from maxillary sinus punctures of 97 patients and 973 scrapings from the nasal cavity. Seeding of biological material and isolation of the microorganisms were performed by classical bacteriological techniques. Antibiotic susceptibility of clinical isolates was determined by disk diffusion methods. The data on microbial sensitivity were interpreted by the EUCAST criteria.

Results

In the samples from nasal cavity and paranasal sinuses, S. epidermidis was most often detected (34.7%, 377/1097); S.viridans (2.2%, 24/1097); S. aureus (1.91%, 21/1097); Klebsiella spp (1%, 11/1097). Detection frequency of S.epidermidis and S.viridans was minimal in the younger age group (up to 5 years), and increased in older groups (>15 years old). Profound suppression of S.epidermidis growth was noted, especially in paranasal sinuses, within 1 month after HSCT in presence of massive antibiotic therapy. High frequency of Klebsiella spp detection was noted in the samples from maxillar sinuses at later terms (2-3 months) after HSCT, at low detection frequency of the pathogen in the specimens from nasal cavity (average 16.3% vs 2.1%, p=2×10^14). In addition, we have estimated frequency of bacterial inoculation within +30 days upon the diagnosis of sinusitis. At the same time, an increased frequency of Pseudomonas spp isolation (1/378 vs 7/217) was revealed in the material from paranasal sinuses.

Conclusion

Bacteriological study of biological samples from maxillary sinuses is of limited value during the 1st month after HSCT accompanied by massive antibiotic therapy which was followed by selection of resistant strains of Klebsiella spp, Pseudomonas spp, E. coli, S. aureus, mainly at the terms of >2 months after HSCT.

Keywords

Hematopoietic stem cell transplantation, paranasal sinuses, microbiota, antibiotic resistance.

Clinical case

A case report of haploidentical hematopoietic stem cell transplantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy after kidney transplantation

Download PDF version

Elena N. Parovichnikova, Vera A. Vasilyeva, Olga A. Aleshina, Mariya V. Dovydenko, Larisa A. Kuzmina, Mikhail Yu. Drokov, Irina A. Lukyanova, Vera V. Troitskaya, Evgenii E. Zvonkov, Alla M. Kovrigina, Valery G. Savchenko

National Medical Research Center for Hematology, Moscow, Russia


Correspondence:
Dr. Vera A. Vasilyeva, PhD, MD, Head Immunochemotherapy Department for BMT patients, National Medical Research Center for Hematology, 4 Novyi Zykovskii Lane, Moscow, 125167, Russia
Phone: +7 (916) 262-23-16
E-mail: vasilievaVA4@mail.ru


Citation: Parovichnikova EN, Vasilyeva VA, Aleshina OA et al. A case report of haploidentical hematopoietic stem cell transplantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy after kidney transplantation. Cell Ther Transplant 2022; 11(1): 50-57.

Post-transplant lymphoproliferative disease (PTLD) is one of the most common complications after organ transplantation. The main goal of PTLD treatment is to achieve stable remission of the disease and preserve the transplanted organ. However, it is not uncommon that after PTLD therapy immunosuppressive therapy for the transplanted organ is returned, which may again lead to a recurrence of PTLD. Autologous hematopoietic stem cell transplantation is a rare option for treatment PTLD. The role of allogeneic hematopoietic stem cell transplantation (HSCT) in PTLD therapy after solid organ transplantation has not been determined, due to the high risks of toxicity for the transplanted organ, the development of a graft-versus-host disease may lead to rejection of the transplanted solid organ, and the presence of a solid organ transplant may increase the rejection of hematopoietic stem cells.

We have described a case report of haploidentical hematopoietic allogeneic stem cell transplantation with TCR αβ+/CD19+ cell depletion for a patient with second remission of diffuse large B-cell lymphoma associated with immunosuppressive therapy for a previously performed allogeneic cadaveric kidney transplantation.

Keywords

Post-transplant lymphoproliferative disease, hematopoietic allogeneic stem cell transplantation, haploidentical, TCR αβ+/CD19+ cell depletion.

Experimental studies

Therapeutic potential of mouse bone marrow mesenchymal stromal cells transplantation in ameliorating of CCL4-induced liver damage (in vivo study)

Download PDF version

Dima Joujeh1, Abduljalil Ghrewaty1, Chadi Soukkarieh2, Adnan Almarrawi1, Jamal Abdul Naser Darwicha3

1 Department of Biotechnology Engineering, Faculty of Technical Engineering, University of Aleppo, Syria
2 Department of Animal Biology, Faculty of Sciences, Damascus University, Damascus, Syria
3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Arab International University, Syria


Correspondence:
Dr. Dima Joujeh, Department of Biotechnology Engineering, Faculty of Technical Engineering, University of Aleppo, Syria
Phone: (+963) 994-046-745
E-mail: dimajoujeh@gmail.com


Citation: Joujeh D, Ghrewaty A, Soukkarieh C et al. Therapeutic potential of mouse bone marrow mesenchymal stromal cells transplantation in ameliorating of CCL4-induced liver damage (in vivo study). Cell Ther Transplant 2022; 11(1): 58-68.

Liver diseases pose a major global health problem. In this study, the effect of bone marrow derived mesenchymal stromal cells MSC(M) in liver damage induced by CCl4 treatment was investigated.

Materials and methods

Balb/c mice were injected by (1 ml/kg body weight) of CCl4 twice a week for 7 weeks. The mice were then intravenously injected with MSC(M) (at the passage 0), or physiological saline (PBS, control group). Four weeks after transplantation, serum levels of ALT, AST, ALP and albumin were measured, liver histopathology was performed, and ELISA technique was carried out to detect the serum levels of IL-4 and IFN-γ.

Results

As compared with PBS-treated animals, MSC(M)- treated group presented with lower levels of ALT and ALP, being also associated with less pronounced changes in serum albumin. Histological study was consistent with biochemical data, suggesting an improvement in MSC(M)-treated group compared with PBS group. Transplantation of MSC(M) increased production of IL-4 and IFN-γ compared to PBS group.

Conclusion

Our results demonstrated that MSC(M) transplantation could facilitate recovery from chemically induced liver damage. Therefore, MSC(M) transplantation may represent a new concept for the treatment of liver diseases.

Keywords

Mice, liver damage, CCl4, bone marrow stromal cells, mesenchymal, cell transplantation.